Seven biotechs eye $2.3B in public offerings after data readouts

FierceBiotechChutes & Ladders—Helus shuffles out CEO after two months, adds experience to science board

FierceBiotechAfter Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?

BioWorldSichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists

BioWorldShanghai Meiyue Biotech Development presents new molecular glue degraders

BioWorldJiangsu Carephar Pharmaceutical describes new AT2 receptor agonists

BioWorldPharma industry faces long haul to get return on investment from AI

FierceBiotechAvalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs

Thermo FisherThermo Fisher Scientific Q1 Earnings Call Highlights - Yahoo Finance

AgilentDoes Agilent (A) Settling Axion Dispute Clarify Its Push Into Cloud Lab Data Recurring Revenues? - simplywall.st

10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - Yahoo Finance

10x Genomics BlogLiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - BioSpace

Thermo FisherThermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking Alpha